CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
Last update: 6 hours ago28.18
-0.87 (-2.99%)
| Previous Close | 29.05 |
| Open | 28.67 |
| Volume | 967,100 |
| Avg. Volume (3M) | 1,074,908 |
| Market Cap | 2,053,418,112 |
| Price / Sales | 1.48 |
| Price / Book | 2.80 |
| 52 Weeks Range |
| Operating Margin (TTM) | -8,344.08% |
| Diluted EPS (TTM) | -1.41 |
| Quarterly Revenue Growth (YOY) | 45,500.00% |
| Total Debt/Equity (MRQ) | 0.03% |
| Current Ratio (MRQ) | 35.30 |
| Operating Cash Flow (TTM) | -78.71 M |
| Levered Free Cash Flow (TTM) | -59.08 M |
| Return on Assets (TTM) | -15.02% |
| Return on Equity (TTM) | -19.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.16% |
| % Held by Institutions | 98.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (HC Wainwright & Co., 166.15%) | Buy |
| 75.00 (Cantor Fitzgerald, 166.15%) | Buy | |
| Median | 61.50 (118.24%) | |
| Low | 23.00 (Scotiabank, -18.38%) | Hold |
| Average | 56.17 (99.33%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 26.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 02 May 2025 | 41.00 (45.49%) | Buy | 29.05 |
| RBC Capital | 29 Apr 2025 | 68.00 (141.31%) | Buy | 26.94 |
| Cantor Fitzgerald | 28 Apr 2025 | 75.00 (166.15%) | Buy | 27.97 |
| HC Wainwright & Co. | 28 Apr 2025 | 75.00 (166.15%) | Buy | 27.97 |
| 31 Mar 2025 | 75.00 (166.15%) | Buy | 24.49 | |
| Scotiabank | 16 Apr 2025 | 23.00 (-18.38%) | Hold | 20.22 |
| Morgan Stanley | 07 Mar 2025 | 55.00 (95.17%) | Buy | 26.72 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| POST LEONARD E | - | 27.97 | -1,000 | -27,970 |
| Aggregate Net Quantity | -1,000 | |||
| Aggregate Net Value ($) | -27,970 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.97 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| POST LEONARD E | Director | 28 Apr 2025 | Automatic sell (-) | 1,000 | 27.97 | 27,970 |
| POST LEONARD E | Director | 28 Apr 2025 | Option execute | 1,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |